Soligenix Enhances Vaccine Stability with ThermoVax® Technology for Global Health Impact

Soligenix Advances Vaccine Stability Through ThermoVax® Technology

Soligenix, Inc., a biopharmaceutical company based in Princeton, N.J., is making significant strides in the field of vaccine development with its proprietary ThermoVax® technology. Recent findings highlight the stability of its ebolavirus vaccines, which include bivalent and trivalent formulations targeting Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus, as well as the CoVaccine HT™ antigen. Conducted in collaboration with Dr. Axel Lehrer from the University of Hawaiʻi at Mānoa, the study underscores that these vaccines maintain their potency after two years of storage at elevated temperatures of up to 40°C (104°F). This remarkable stability has broad implications for vaccine distribution and accessibility, especially in regions prone to viral outbreaks.

The study's results are particularly promising, showing that the vaccines can elicit robust immune responses in mice and provide up to 100% protection in non-human primates. This level of efficacy indicates that the formulations could play a crucial role in public health strategies, especially in virus-endemic areas. The single-vial design of the vaccines not only simplifies logistics but also enhances the feasibility of ambient temperature shipping. This aspect is critical in resource-limited settings where cold-chain logistics often pose significant challenges to vaccination efforts.

Dr. Christopher J. Schaber, President and CEO of Soligenix, emphasizes that the ThermoVax® platform is revolutionizing vaccine stability and accessibility. By successfully stabilizing vaccines against various threats, including ricin toxin and COVID-19, the company is positioning its protein subunit vaccines as a promising alternative due to their safety and reduced cold-storage requirements. As global vaccination strategies evolve, Soligenix's advancements in vaccine technology could facilitate more efficient immunization efforts worldwide, thereby addressing the challenges posed by infectious diseases.

In addition to its vaccine initiatives, Soligenix is actively pursuing treatments for rare diseases through its Specialized BioTherapeutics segment. The company is advancing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), with regulatory approvals expected following the completion of its second Phase 3 study. Furthermore, Soligenix’s Public Health Solutions segment continues to make progress with candidates like RiVax®, aimed at ricin toxin, and CiVax™ for COVID-19 prevention.

As Soligenix prepares for its participation in the H.C. Wainwright 27th Annual Global Investment Conference, the company aims to engage with potential partners and stakeholders regarding its innovative therapies and vaccines. Interested parties can access the presentation and arrange one-on-one meetings through the conference's scheduling platform.